Medical - Healthcare Plans · NYSE
Current Price
$64.54
Intrinsic Value
Outside reliable range
COMPETITIVE MOAT
↑Government Contracts
Centene's substantial reliance on government contracts for Medicare and Medicaid provides a stable, recurring revenue stream. These contracts are difficult for competitors to replicate due to regulatory hurdles and established relationships.
↑Scale and Network Effects
As a large managed care provider, Centene benefits from economies of scale in negotiating provider rates and administrative efficiencies. Its extensive network of healthcare providers offers a competitive advantage in serving diverse populations.
↑Focus on Underserved Markets
Centene's strategic focus on serving low-income and vulnerable populations, often through government-sponsored programs, creates a niche market with less intense competition from traditional commercial insurers.
INVESTMENT RISKS
↓Regulatory and Policy Changes
Centene's business is heavily dependent on government healthcare policies. Changes in Medicare or Medicaid regulations, reimbursement rates, or eligibility criteria could significantly impact profitability.
↓Competition and Margin Pressure
The healthcare insurance market is highly competitive. Centene faces pressure from both large national insurers and smaller regional players, which can lead to compressed profit margins.
↓Execution and Integration Risks
Centene has grown through acquisitions. Integrating new businesses and managing operational complexities across a large, diverse organization presents ongoing execution risks and potential cost overruns.
Base case
Base case assumptions: 20.0% annual growth, 10.0% discount rate, 5x exit multiple, 5 year projection. Data as of 2026-06-29.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Centene Corp. respond.
Open DCF Calculator for CNCCentene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Revenue/Share (TTM)
$402.59
FCF/Share (TTM)
$12.90
ROIC (TTM)
-17.7%
ROE (TTM)
-28.7%
P/FCF
5.0x
EV/EBITDA
-6.1x
FCF Yield
19.91%
Debt/Equity
0.76x
Based on trailing twelve-month data, CNC shows a free cash flow per share of $12.90 and a ROIC of -17.7%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 5.0x and FCF yield of 19.91% are important context metrics when evaluating CNC's stock valuation relative to peers.
Centene Corp. currently generates $12.90 in free cash flow per share. At the current price of $64.54, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
CNC trades at a P/FCF ratio of 5.0x with a free cash flow yield of 19.91%. This relatively low P/FCF may suggest the stock is attractively priced relative to its cash generation. However, whether CNC is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
To perform a DCF valuation on Centene Corp.: (1) Start with the trailing free cash flow per share ($12.90) as the base, (2) project future FCF growth over 5-10 years based on Medical - Healthcare Plans industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting CNC's risk profile — with a debt-to-equity of 0.76x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Centene Corp., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Healthcare Plans trends, then discounting those amounts to today's dollars. CNC's ROIC of -17.7% suggests the company may face challenges generating returns above its cost of capital.
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For CNC, with a debt-to-equity ratio of 0.76x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of -6.1x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
DCF and P/E value CNC with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-29. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.